axitinib,sunitinib,pembrolizumab
merck,pfizer
['kn-42', 'axitinib', 'pembro', 'congrat', 'rcc,(-irccs),(-srcc),(-urcc)', 'kn-426']
#asco23 presents the long term follow up of kn-426 trial with pembrolizumab + axitinib in 1st line mrcc #kidneycancer after a 67 month, robust benefit present after a long term followup. congrats to all. 
Medical Oncologist. Editor-in-chief: @ASCO Daily News; Presidential Endowed Chair, @HuntsmanCancer (NCI-CCC) @UUtah, FCOI https://t.co/ywWAdZmBWt